Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective

AIDS

Volumn 13, Issue 12, 1999, Pages 1549-1556

  Bell, Jensa C ^a   Rose, David N ^b   Sacks, Henry S ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Africa; Cost effectiveness analysis; Decision analysis; Developing countries; Economics; Isoniazid; Prevention; Pyrazinamide; Rifampin; Tuberculosis; Uganda

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AFRICA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; SIDE EFFECT; TUBERCULOSIS; UGANDA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; QUALITY OF LIFE; SURVIVAL ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UGANDA;

EID: 0032858146     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199908200-00016     Document Type: Article

References (40)

1. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993, 7:1569-1579.
2. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV infected patients. Lancet 1989, 2:1502-1504.
3. Edlin B, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:1514-1521.
4. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med 1992, 326:231-235.
5. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
6. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992, 268:504-509.
7. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993, 119:194-198.
8. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345-1349.
9. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV infected persons; a prospective cohort study. JAMA 1995, 274:143-148.
10. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis 1991, 143:501-504.
11. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ettner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995, 151:129-135.
12. Leroy V, Salmi LR, Dupon M, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease; a cohort study in Bordeaux, France, 1988-1994. Am J Epidemiol 1997, 145:293-300.
13. De Cock KM, Grant A, Porter JD. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 1995, 345:833-836.
14. O'Brien RJ, Perriens JH. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 1995, 9:665-673.
15. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998, 338:853-860.
16. Muller O, Corrah T, Katabira E, Plummer F, Mabey D. Antiretroviral therapy in sub-Saharan Africa. Lancet 1998, 351:68.
17. Okello DO. Resource utilization patterns in patients with acquired immunodeficiency syndrome (AIDS). East Afr Med J 1994, 71:816-817.
18. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272.
19. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997, 337:801-808.
20. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:786-792.
21. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998, 317:625-629.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1253-1258.
23. Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis. Ann Intern Med 1998, 129:779-786.
24. Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 1983, 3:419-458.
25. Wadhawan D, Hira S, Mwansa N, Sunkutu R, Adera P, Per ne P. Preventive tuberculosis chemotherapy with isoniazid (INH) among patients infected with HIV-1. IXth International Conference on AIDS in affiliation with the IVth STD World Congress. Berlin, June 1993 [abstract PO-B07-114].
26. Hawken MP, Meme HK, Elliot LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: results of a randomized controlled trial. AIDS 1997, 11:875-882.
27. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Resp Dis 1992, 145:494-497.
28. Salpeter SR. Fatal isoniazid-induced hepatitis; its risk during chemoprophylaxis. West J Med 1993, 159:560-564.
29. Saunderson PR. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. Soc Sci Med 1995, 40:1203-1212.
30. Aisu T, Raviglione MC, vanPragg E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995, 9:267-273.
31. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997, 11:919-925.
32. Masobe P, Lee T, Price M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients - a least cost analysis. S Afr Med J 1995, 85:75-81.
33. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:54-62.
34. Murray C, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990, 65:6-24.
35. Sutherland J, Fayers PM. The association of the risk of tuberculosis infection with age. Bull Int Union Tuberc Lung Dis 1975, 50:70-81.
36. Mulder DW, Nunn AJ, Wagner HV, Kamali A, Kengeya-Kayondo JF. HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994, 8:87-92.
37. Tanzanian Ministry of Health, National AIDS Control Programme: HIV/AIDS/STDSurveillance. Report No. 10, December 1995. Dar es Salaam: Epidemiology Unit, National AIDS Control Programme. June, 1996.
38. Comstock GM. Epidemiology of tuberculosis. Am Rev Respir Dis 1982, 125:8-15.
39. Nunn AJ, Mulder DW, Kamali A, Ruberantwari A, Kengeya-Kayondo JF, Whitworth J. Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study. BMJ 1997, 315:767-771.
40. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"): 1. Validation of the method. Am J Med 1982, 73:883-897.